TD Cowen downgraded Alpine Immune Sciences (ALPN) to Hold from Buy without a price target after the company entered a definitive agreement to be acquired by Vertex Pharmaceuticals (VRTX) for $4.9B or $65 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN:
- Biotech Alert: Searches spiking for these stocks today
- Alpine Immune Sciences downgraded to Market Perform from Outperform at Leerink
- Analyst thinks this drugmaker could be next after Alpine’s $4.9B acquisition
- DoorDash upgraded, Airbnb downgraded: Wall Street’s top analyst calls
- Wedbush downgrades Alpine Immune, sees takeout deal closing
